Aiming to explore novel and selective inhibition strategies for SF3B1 mutations recurrent in hematologic malignancies we employed a cavity detector algorithm to pinpoint druggable (allosteric) sites, distinct from the BPA binding cavity. Here, SF3B1 is linked to hematologic disorder.